<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01532791</url>
  </required_header>
  <id_info>
    <org_study_id>AAAB1425</org_study_id>
    <secondary_id>5P01HD032062</secondary_id>
    <nct_id>NCT01532791</nct_id>
  </id_info>
  <brief_title>Natural History Study - Mitochondrial Disease</brief_title>
  <official_title>Mitochondrial Encephalomyopathies and Mental Retardation: Investigations of Clinical Syndromes Associated With MtDNA Point Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carriers of the m.3242A&gt;G mutation often have clinical symptoms which can include migraines,
      seizures, strokes, hearing loss, balance issues, gastrointestinal issues, and many other
      symptoms. The investigators would like to learn more about these disorders and have designed
      a &quot;Natural History Study&quot; to monitor these conditions over time so that physicians and
      scientists can not only understand the problems that patients have, but work on developing
      treatments. The focus of the current work is to evaluate known mutation carriers of the
      m.3243A&gt;G (mitochondrial DNA) and their maternal relatives (carrier status not a requirement
      for participation). Paternal relatives will serve as controls. This study involves no
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate the neurological and biochemical consequences of
      the m.3243 A&gt;G mutation. Mitochondria are the powerhouses of the cell and are controlled by
      nuclear genetic material (DNA) and mitochondrial (mt) DNA. Mitochondrial DNA mutations impair
      mitochondrial function, and cause cellular energy failure. These mutations, when present in
      high abundance, cause neurological signs and symptoms that are clinically obvious. The
      investigators hypothesize that these mutations, when present in lesser abundance, will cause
      measurable alterations in the patient's neuropsychological profile and cerebral energy
      profile. This study does not involve any experimental or approved therapy. The investigators
      will evaluate the patient's condition with blood/urine tests, neurological exam, MRI/MRS,
      questionnaires, motor skills functioning, serum and urine biomarkers, and genetic testing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MRI/MRS</measure>
    <time_frame>2-3 years</time_frame>
    <description>Evaluate structure and function in brain and muscle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>2-3 years</time_frame>
    <description>Evaluate various biomarkers of disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor skills</measure>
    <time_frame>2-3 years</time_frame>
    <description>6 minute walk test to evaluate motor skills</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>2-3 years</time_frame>
    <description>Evaluate cognitive function through neuropsychological testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical symptoms</measure>
    <time_frame>2-3 years</time_frame>
    <description>Evaluate clinical symptoms through medical history questionnaires and physical exam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mutation load</measure>
    <time_frame>2-3 years</time_frame>
    <description>Evaluate heteroplasmy through blood,urine and skin fibroblast evaluations</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>MELAS or m.3243 A&gt;G Mitochondrial DNA Mutation Carrier</condition>
  <arm_group>
    <arm_group_label>mtDNA mutation</arm_group_label>
    <description>m.3243 A&gt;G carriers and their maternal relatives Other mutations in the mitochondrial genome may be included</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>controls (people not maternally related to mutation carriers) Preference is for married in relatives</description>
  </arm_group>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      skin fibroblast blood urine buccal cells hair samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Carriers of the m.3243A&gt;G mitochondrial DNA point mutation, and their maternal relatives
        (carrier status documentation not required.). All patients suspected of having an mtDNA
        point mutation regardless of age, health status, gender, race, or ethnicity will be
        evaluated. The minimal age of entry into the study will be 4 years or older. We will also
        evaluate controls (often these are married in relatives).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Known carrier of a the m.3243 A&gt;G mitochondrial mutation, ,or Maternally related to someone
        who carries the m.3243A&gt;G mitochondrial mutation.

        A family member who is not maternally related to someone who carries the m.3243A&gt;G
        mitochondrial mutation

        Exclusion Criteria:

          -  Younger than 4 years of age

          -  No confirmed m.3243 A&gt;G mitochondrial DNA mutation in the family.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darryl De Vivo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>dcd1@columbia.edu</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kris Engelstad, MS</last_name>
    <phone>2123056834</phone>
    <email>ke4@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Darryl De Vivo, MD</last_name>
    <phone>2123055244</phone>
    <email>dcd1@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris Engelstad, MS</last_name>
      <phone>212-305-6834</phone>
      <email>ke4@cumc.columbia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.giblinlab.org</url>
    <description>general website for our available clinical studies</description>
  </link>
  <reference>
    <citation>Weiduschat N, Kaufmann P, Mao X, Engelstad KM, Hinton V, DiMauro S, De Vivo D, Shungu D. Cerebral metabolic abnormalities in A3243G mitochondrial DNA mutation carriers. Neurology. 2014 Mar 4;82(9):798-805. doi: 10.1212/WNL.0000000000000169. Epub 2014 Jan 29.</citation>
    <PMID>24477106</PMID>
  </reference>
  <reference>
    <citation>Kaufmann P, Engelstad K, Wei Y, Kulikova R, Oskoui M, Sproule DM, Battista V, Koenigsberger DY, Pascual JM, Shanske S, Sano M, Mao X, Hirano M, Shungu DC, Dimauro S, De Vivo DC. Natural history of MELAS associated with mitochondrial DNA m.3243A&gt;G genotype. Neurology. 2011 Nov 29;77(22):1965-71. doi: 10.1212/WNL.0b013e31823a0c7f. Epub 2011 Nov 16.</citation>
    <PMID>22094475</PMID>
  </reference>
  <reference>
    <citation>Mehrazin M, Shanske S, Kaufmann P, Wei Y, Coku J, Engelstad K, Naini A, De Vivo DC, DiMauro S. Longitudinal changes of mtDNA A3243G mutation load and level of functioning in MELAS. Am J Med Genet A. 2009 Feb 15;149A(4):584-7. doi: 10.1002/ajmg.a.32703.</citation>
    <PMID>19253345</PMID>
  </reference>
  <reference>
    <citation>Kaufmann P, Engelstad K, Wei Y, Kulikova R, Oskoui M, Battista V, Koenigsberger DY, Pascual JM, Sano M, Hirano M, DiMauro S, Shungu DC, Mao X, De Vivo DC. Protean phenotypic features of the A3243G mitochondrial DNA mutation. Arch Neurol. 2009 Jan;66(1):85-91. doi: 10.1001/archneurol.2008.526.</citation>
    <PMID>19139304</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2012</study_first_submitted>
  <study_first_submitted_qc>February 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2012</study_first_posted>
  <last_update_submitted>August 10, 2016</last_update_submitted>
  <last_update_submitted_qc>August 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Darryl C. De Vivo</investigator_full_name>
    <investigator_title>Sidney Carter Professor of Neurology and Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>MELAS</keyword>
  <keyword>mitochondrial DNA mutation</keyword>
  <keyword>mtDNA mutation</keyword>
  <keyword>mitochondrial DNA</keyword>
  <keyword>mitochondria</keyword>
  <keyword>m.3243A&gt;G mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitochondrial Diseases</mesh_term>
    <mesh_term>Mitochondrial Encephalomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>When applicable, manuscript(s) regarding data will be submitted for publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

